MTNBHealthcare · BiotechnologyMTNB Stock Forecast: Matinas BioPharma Holdings, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 20 Aug 2026 — in the lower half.
MTNB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Matinas BioPharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
MTNB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MTNB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2024 | Maxim Group | Downgrade | Hold | — |
| 11 Oct 2023 | BTIG | Reinstates | Buy | $3.00 |
| 31 Jan 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2020 | Aegis Capital | Maintains | Buy | — |
| 27 Jan 2020 | Piper Sandler | Initiates | Overweight | — |
| 24 Jan 2020 | SunTrust Robinson Humphrey | Initiates | Buy | — |
| 26 June 2019 | H.C. Wainwright | Initiates | Buy | — |
| 26 June 2019 | HC Wainwright & Co. | Initiates | Buy | — |
| 17 May 2019 | BTIG | Initiates | Buy | — |
| 17 May 2019 | BTIG Research | Initiates | Buy | — |
| 11 Feb 2019 | Roth Capital | Initiates | Buy | — |
| 13 Nov 2018 | Maxim Group | Maintains | Buy | — |
| 13 Aug 2018 | Maxim Group | Maintains | Buy | — |
| 10 July 2018 | Maxim Group | Maintains | Buy | — |
| 1 Nov 2016 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MTNB appears on the weeks it earns a place.
MTNB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Matinas BioPharma Holdings, Inc. (MTNB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.1×
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- −0.3×
Cheaper than 77% of US stocks
Cheaper than 81% of US stocks
Cheaper than 62% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −141.2%
- Return on assets
- −56.2%
- Dividend yield
- —
Higher than 10% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MTNB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Matinas BioPharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about MTNB stock
Is MTNB stock a buy right now?
Of the 1 analysts covering Matinas BioPharma Holdings, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Matinas BioPharma Holdings, Inc. 47 out of 100 across roughly 4,600 US stocks as at 20 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MTNB?
As at 20 Aug 2026, Matinas BioPharma Holdings, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
What is the MTNB stock forecast for 2030?
No analyst covering Matinas BioPharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTNB are extrapolating price history, which says nothing about the business.
How has MTNB stock performed over the past year?
Matinas BioPharma Holdings, Inc. returned -88.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Matinas BioPharma Holdings, Inc. do?
Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for unmet medical needs.
About Matinas BioPharma Holdings, Inc.
Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for unmet medical needs. Its primary function lies in the creation and advancement of lipid nano-crystal delivery technology, which aims to enhance the bioavailability and efficacy of pharmaceuticals. This company has a strategic focus on infectious diseases and rare disorders, addressing significant gaps in existing therapeutic options. Matinas Biopharma's innovative delivery platforms are designed to optimize drug exposure, enhance safety profiles, and enable oral dosing of complex molecules, which can potentially transform the treatment landscape. Operating within the biotechnology sector, the company impacts both healthcare and pharmaceutical industries by striving to improve the delivery and accessibility of treatments. By leveraging its proprietary technology, Matinas Biopharma plays a crucial role in the market by providing advanced solutions that could potentially reformulate how certain medications are administered, contributing to a broader goal of enhancing patient outcomes and quality of life.
CEO Mr. Jerome D. Jabbour J.D. · 2 employees · United States · https://www.matinasbiopharma.com